These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 29353277)

  • 21. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
    Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Atherosclerosis; 2015 Aug; 241(2):450-4. PubMed ID: 26074319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Low-Density Lipoprotein Cholesterol and Cardiovascular Disease Risk Across Chronic Kidney Disease Stages (Data from 1.9 Million United States Veterans).
    Hashemi L; Hsiung JT; Arif Y; Soohoo M; Jackson N; Gosmanova EO; Budoff M; Kovesdy CP; Kalantar-Zadeh K; Streja E
    Am J Cardiol; 2022 May; 170():47-55. PubMed ID: 35300833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Statin use and low-density lipoprotein cholesterol levels in patients aged 75 years and older with acute coronary syndrome in China].
    Xing YY; Liu J; Liu J; Hao YC; Yang N; Zhou MG; Zhao D;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 May; 47(5):351-359. PubMed ID: 31142078
    [No Abstract]   [Full Text] [Related]  

  • 24. Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?
    Vrablik M; Corsini A; Tůmová E
    Curr Atheroscler Rep; 2022 Mar; 24(3):161-169. PubMed ID: 35174437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy.
    Mortensen MB; Afzal S; Nordestgaard BG; Falk E
    J Am Coll Cardiol; 2015 Dec; 66(24):2699-2709. PubMed ID: 26700832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study.
    Madsen CM; Varbo A; Nordestgaard BG
    Eur Heart J; 2018 Feb; 39(7):610-619. PubMed ID: 29182745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.
    Nordestgaard BG
    Circ Res; 2016 Feb; 118(4):547-63. PubMed ID: 26892957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis).
    Nasir K; Bittencourt MS; Blaha MJ; Blankstein R; Agatson AS; Rivera JJ; Miedema MD; Sibley CT; Shaw LJ; Blumenthal RS; Budoff MJ; Krumholz HM
    J Am Coll Cardiol; 2015 Oct; 66(15):1657-68. PubMed ID: 26449135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.
    Stroes ES; Thompson PD; Corsini A; Vladutiu GD; Raal FJ; Ray KK; Roden M; Stein E; Tokgözoğlu L; Nordestgaard BG; Bruckert E; De Backer G; Krauss RM; Laufs U; Santos RD; Hegele RA; Hovingh GK; Leiter LA; Mach F; März W; Newman CB; Wiklund O; Jacobson TA; Catapano AL; Chapman MJ; Ginsberg HN;
    Eur Heart J; 2015 May; 36(17):1012-22. PubMed ID: 25694464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on the detection and treatment of atherogenic low-density lipoproteins.
    Sniderman A; Kwiterovich PO
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):140-7. PubMed ID: 23422241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review.
    Cherepanov D; Bentley TGK; Hsiao W; Xiang P; O'Neill F; Qian Y; Yurgin N; Beenhouwer D
    Curr Med Res Opin; 2018 Mar; 34(3):459-473. PubMed ID: 29105492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV.
    Puri R; Bansal M; Mehta V; Duell PB; Wong ND; Iyengar SS; Kalra D; Nair DR; Nanda NC; Narula J; Deedwania P; Yusuf J; Dalal JJ; Shetty S; Vijan VM; Agarwala R; Kumar S; Vijay K; Khan A; Wander GS; Manoria PC; Wangnoo SK; Mohan V; Joshi SR; Singh B; Kerkar P; Rajput R; Prabhakar D; Zargar AH; Saboo B; Kasliwal RR; Ray S; Bansal S; Rabbani MU; Chhabra ST; Chandra S; Bardoloi N; Kavalipati N; Sathyamurthy I; Mahajan K; Pradhan A; Khanna NN; Khadgawat R; Gupta P; Chag MC; Gupta A; Murugnathan A; Narasingan SN; Upadhyaya S; Mittal V; Melinkeri RP; Yadav M; Mubarak MR; Pareek KK; Dabla PK; Nanda R; Mohan JC
    J Clin Lipidol; 2024; 18(3):e351-e373. PubMed ID: 38485619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twenty-year epidemiologic study on LDL-C levels in relation to the risks of atherosclerotic event, hemorrhagic stroke, and cancer death among young and middle-aged population in China.
    Zhang X; Liu J; Wang M; Qi Y; Sun J; Liu J; Wang Y; Hao Y; Li Y; Zhou M; Zhao D
    J Clin Lipidol; 2018; 12(5):1179-1189.e4. PubMed ID: 30037589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan.
    Yeh YT; Yin WH; Tseng WK; Lin FJ; Yeh HI; Chen JW; Wu YW; Wu CC;
    PLoS One; 2017; 12(10):e0186861. PubMed ID: 29073192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.